Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Large-scale testing (Phase 3)Ended earlyNCT02145598
What this trial is testing

Treatment Optimization in Patients With Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dr. med. Lars-Olof Muegge 85
Early research (Phase 1)Active Not RecruitingNCT04754945
What this trial is testing

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Who this might be right for
AL Amyloidosis
Emory University 11
Early research (Phase 1)Study completedNCT02924402
What this trial is testing

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Who this might be right for
B-cell Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
Xencor, Inc. 154
Testing effectiveness (Phase 2)Study completedNCT00075881
What this trial is testing

Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Looking for participantsNCT04776395
What this trial is testing

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Plasma Cell Myeloma
Emory University 68
Testing effectiveness (Phase 2)UnknownNCT04935580
What this trial is testing

Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01206205
What this trial is testing

Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

Who this might be right for
Multiple Myeloma
University Hospital, Toulouse 31
Early research (Phase 1)Ended earlyNCT02716805
What this trial is testing

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Who this might be right for
Multiple Myeloma
Ludwig Institute for Cancer Research 6
Not applicableStudy completedNCT04409314
What this trial is testing

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of California, San Francisco 23
Testing effectiveness (Phase 2)Study completedNCT01079936
What this trial is testing

Lenalidomide and High-Dose Melphalan

Who this might be right for
MyelomaStem Cell Transplantation
M.D. Anderson Cancer Center 61
Testing effectiveness (Phase 2)Study completedNCT00003399
What this trial is testing

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
University of Maryland, Baltimore
Large-scale testing (Phase 3)Study completedNCT01311687
What this trial is testing

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Who this might be right for
Multiple Myeloma
Celgene 455
Testing effectiveness (Phase 2)Ended earlyNCT02943473
What this trial is testing

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Who this might be right for
High Risk Smoldering Multiple Myeloma
Icahn School of Medicine at Mount Sinai 9
Testing effectiveness (Phase 2)Study completedNCT00112827
What this trial is testing

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaSmoldering Multiple MyelomaStage I Multiple Myeloma+2 more
City of Hope Medical Center 54
Early research (Phase 1)Study completedNCT00003107
What this trial is testing

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+8 more
Indiana University
Very early researchLooking for participantsNCT06398457
What this trial is testing

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Who this might be right for
Hematologic MalignancyBone Marrow Transplant RejectionAcute Myeloid Leukemia (AML)+9 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 8
Very early researchStudy completedNCT04862676
What this trial is testing

Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT

Who this might be right for
Myeloma
University of Rochester 29
Not applicableEnded earlyNCT02900248
What this trial is testing

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

Who this might be right for
NeoplasmsLung NeoplasmsColon Neoplasms+22 more
CureOne 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT06183489
What this trial is testing

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
European Myeloma Network B.V. 50
Next Page